Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod Alfa Injection prospective observational study in generalized myasthenia gravis
ChiCTR2200066880Phase 4Not yet recruiting
- Sponsor
- Hainan General Hospital
- Start
- Jan 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by Hainan General Hospital. Primary endpoint: MG-ADL reduction at week 4. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2200066880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066880.